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ABSTRACT
Despite the best available agents to prevent mucositis, most patients receiving high-dose chemoradiotherapy
regimens experience severe mucositis, and new therapies are needed. In this study, we evaluated the safety and
tolerability of a milk-derived growth factor extract (PV701 mouthwash) intended to prevent oral mucositis
(OM) after carmustine, etoposide, cytosine arabinoside, and melphalan (BEAM) chemotherapy. PV701 mouth-
wash (15 mL  13.5 mg/mL) was administered 6 times a day for 12 days, from day 6 to day 5, to patients
with lymphoma, who were given BEAM on day6 to day2, with autologous stem cells infused on day 0. Dose
de-escalation of PV701 was planned if dose-limiting toxicities occurred. The severity and duration of OM, the
duration of enteral/parenteral feeding, the requirement for intravenous opiates, and admission to intensive
care were recorded. Outcomes were also compared with those of historical control patients. Nine patients
received PV701 13.5 mg/mL. PV701 was well tolerated, and no dose-limiting toxicities were observed.
Compared with 89 historical controls, the 9 PV701-treated patients had significantly less frequent grade 2 or
3 OM (P  .0006) and had grade >3 OM for an estimated 5 fewer days (P  .0003). There was a reduction in
the need for enteral/parenteral feeding (P  .012), its duration (P  .010), and its frequency (P  .022) and in
the duration of intravenous opiates (P  .0006). We conclude that PV701 mouthwash is readily administered
with minimal side effects at a dose of 1215 mg/d, and further investigation of this agent is warranted.
© 2005 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
High-dose chemoradiotherapy with autologous
eripheral blood stem cell transplantation (AuSCT) is
requently used for patients with relapsed non-
odgkin and Hodgkin lymphoma. One of the most
ommon high-dose chemotherapy (HDT) regimens is
he combination of carmustine, etoposide, cytosine
rabinoside, and melphalan (BEAM) [1-9]. Oral mu-
ositis (OM) is a common side effect of HDT, and
rade 2 to 3 mucositis is reported to occur in most
atients who receive BEAM [1,2,4-11]. Symptoms can o
12e so severe that food and ﬂuid intake, gum and dental
ondition, and speech are compromised. The severity
f mucositis also correlates with subsequent bactere-
ia and sepsis (see review [12]). Furthermore, after
DT, hospitalization may be prolonged while mu-
ositis resolves and oral intake improves [13].
Clinical practice guidelines for the prevention and
reatment of mucositis have recently been published
14]. Treatments used to relieve the symptoms of
stablished mucositis in the HDT setting include bi-
arbonate-based mouthwashes, local anesthetic, and
piate-based mouthwashes, aimed to relieve pain and
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Mucositis Therapy with Milk-Protein Extract
Biscomfort until the mucosa heals. Investigators have
xamined therapies to prevent mucositis (see reviews
12,14]), including the use of chlorhexidine, oral bac-
erial decontamination, l-glutamine and the related
ompound AES-14 [15], sucralfate, and iseganan, an
nalogue of protegrin 1 [16]. Benzydamine has also
emonstrated efﬁcacy for preventing mucositis in the
adiotherapy setting (see review [14]). Biological-re-
ponse modiﬁers, cytokines, and biologically active
rowth factors have been used in an attempt to reduce
he occurrence of OM. These include pentoxifylline,
riclosan, granulocyte-macrophage colony-stimulat-
ng factor, interleukin 11, and transforming growth
actor  [14]. However, despite promising results with
number of these treatments, in general, only modest
eneﬁts have been observed, and outcomes have not
een consistently reproducible [14]. Amifostine, which
cavenges free radicals preferentially in nontumor tis-
ue, when used in the AuSCT setting, seems to reduce
he severity of mucositis, thus consequently allowing a
ubstantial dose escalation of melphalan [12]. Palifer-
in, recombinant human keratinocyte growth factor,
as recently been demonstrated to be effective in re-
ucing mucositis after total body irradiation–based
onditioning and AuSCT. However, despite its clear
fﬁcacy, two thirds of patients still experienced grade
or 4 mucositis [17]. The level of evidence from most
ther trials has been low, and consequently the re-
ently published clinical practice guidelines (published
efore the results of the palifermin trial) did not rec-
mmend any routine strategies [14]. Thus, although
ew agents seem to be affecting our ability to reduce
ucositis, most AuSCT patients still experience sub-
tantial mucositis, and there is a need to continue to
xplore novel methods to prevent mucositis in this
etting.
PV701 is a mouthwash that contains a number of
aturally occurring growth factors contained in the
hey fraction of milk. These growth factors include
embers of the transforming growth factor , plate-
et-derived growth factor, insulin-like growth factor,
broblast growth factor, and epidermal growth factor
amilies. In addition, the mouthwash contains other
ioactive proteins with bacteriostatic properties that
ay prevent secondary tissue damage by opportunistic
nfectious agents [18-20]. Although the growth factors
n PV701 comprise only a small fraction of total milk
roteins, they have been shown to exert a cytoprotec-
ive effect on cultured epithelial cells and to enhance
he mitogenesis and migration of a variety of cell lines
21,22]. In vivo studies have shown that the adminis-
ration of milk-derived growth factors enhances the
ealing of incisional wounds, reduces the severity of
M in 5-ﬂuorouracil–treated hamsters, and reduces in-
estinal mucositis in methotrexate-treated rats [20-25].
A previous phase Ia trial in 24 healthy volunteersemonstrated the safety and acceptability of PV701 at a
B&MToses up to 1010 mg/d based on end points such as
dverse events, clinical laboratory abnormalities, and
evelopment of antibodies to PV701 [24]. This report
escribes the results of an open-label phase Ib trial
onducted in patients with lymphoma who underwent
EAM chemotherapy and AuSCT and received
V701 mouthwash, as well as data comparing the
utcomes from 9 PV701-treated patients with those
rom a group of 89 historical control patients treated
t the Peter MacCallum Cancer Centre (PMCC).
ETHODS
ollection of Historical Control Data
Historical control patients were identiﬁed from
he PMCC Hematology Unit transplant database. Pa-
ients with Hodgkin lymphoma or non-Hodgkin lym-
homa were eligible for this analysis if they were aged
8 years or older at the time of transplantation and
ere treated with high-dose BEAM chemotherapy at
MCC between January 1990 and September 2000.
lthough 92 patients satisﬁed these criteria, there
ere insufﬁcient records available for 3 of these pa-
ients; thus, 89 patients were included in the analysis.
ll data were extracted from the prospectively col-
ected AuSCT data forms and entered onto the his-
orical patient database used for this trial. Before the
hase Ib trial was initiated, the historical database was
nterrogated to establish dose-limiting toxicities
DLTs) for planned dose modiﬁcations of PV701 (see
elow).
ligibility Criteria for Phase Ib Trial
Adult patients with lymphoma who were under-
oing BEAM with AuSCT were consecutively re-
ruited during the period of the study. Patients were
equired to have an Eastern Cooperative Oncology
roup performance status less than 3 and were ex-
luded if they had allergies to dairy products, uncon-
rolled diabetes, any sign of mucosal damage or
rauma, esophageal or stomach cancer, primary (un-
esected) cancer of the colon or rectum, or cancer of
he oral cavity or tongue.
igh-Dose Therapy and AuSCT
High-dose BEAM administration consisted of car-
ustine (300 mg/m2, day 6), melphalan (140 mg/
2, day 6), cytosine arabinoside (200 mg/m2, twice
aily, day 5 to day 2), and etoposide (100 mg/m2,
wice daily, day 5 to day 2). Autologous peripheral
lood stem cells were infused on day 0. Throughout
he trial period, all patients received standard support-
ve care according to our institutional protocols.
hese included granulocyte colony-stimulating factor
5 g/kg/d subcutaneously) from day 1 until the
bsolute neutrophil count was 1.0  109/L for 2
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5onsecutive days or 5.0  109/L on a single day.
atients who had positive herpes simplex serology
ere given valacyclovir (500 mg daily by mouth) or, if
hey unable to tolerate oral medications, intravenous
IV) acyclovir (250 mg/kg every 8 hours). Patients
ere also given ﬂuconazole (200 mg) and ranitidine
50 mg by mouth twice daily or 50 mg every 6 hours
V. Prophylactic antifungals and antivirals were con-
inued until the absolute neutrophil count was1.0
09/L. Patients routinely received education regard-
ng mouth hygiene, which included regular mouth
inses and avoidance of aggressive tooth brushing.
Routine therapy for established mucositis included
icarbonate-based mouthwash, and that for grade 2 or
mucositis included cocaine-based mouthwash. IV
piates were introduced if patients were unable to
olerate any ﬂuids despite maximum oral and topical
nalgesic measures. Supplemental feeding was used
ccording to our institutional protocol: enteral feed-
ng (usually by nasogastric tube) was instituted if there
as inadequate oral intake for 4 days. Total paren-
eral nutrition was initiated (or replaced enteral feed-
ng) if there were3 episodes of vomiting in 24 hours,
4 watery bowel actions in 24 hours, ileus, peritonitis,
hort-bowel syndrome, severe enterocolitis, acute
ancreatitis, bowel obstruction, or severe mucositis or
sophagitis that prevented insertion of a nasogastric
ube.
rading of Toxicities
OM was graded by the trial investigators accord-
ng to the National Cancer Institute’s Common Tox-
city Criteria for bone marrow transplant patients
NCI-CTC (BMT)]. Brieﬂy, mucositis was classiﬁed
s follows: grade 1, painless ulcers, erythema, or mild
oreness in the absence of lesions; grade 2, painful
rythema, edema or ulcers but can swallow; grade 3,
ainful erythema, edema, or ulcers preventing swal-
owing or requiring hydration or parenteral (or en-
eral) nutritional support; and grade 4, severe ulcer-
tion requiring prophylactic intubation or resulting in
ocumented aspiration pneumonitis. The duration of
nteral/parenteral feeding was recorded, and we also
sed the oral assessment guide to better document
M in the trial patients [26]. This was not used for the
istorical control group because of limited documen-
ation. Daily assessment of trial patients was per-
ormed by trained medical staff and conﬁrmed by the
rial nurses. This continued until OM resolved to
CI-CTC (BMT) grade 2 for a minimum of 10
ays after the last dose of trial medication and then 3
imes per week until the exit evaluation (day 33).
he requirement for and duration of IV opiates and
nteral/parenteral feeding and any admission to the
ntensive care unit (ICU) were also recorded. m
14V701 Manufacture
The PV701 drug product contains proteins with
asic charge, including lactoperoxidase, immunoglob-
lin, and xanthine dehydrogenase. A host of minor
roteins comprise less than 5% of the mixture, includ-
ng -lactoglobulin, RNA-ase, poly(A) polymerase,
nd growth factors. Several classes of growth factors
ave been identiﬁed in PV701 that have a direct pro-
iferative or inhibitory action on different cells
hrough receptor binding and are involved in the tis-
ue repair process, including insulin-like growth fac-
ors I and II, ﬁbroblast growth factors, platelet-de-
ived growth factor, transforming growth factor ,
nd betacellulin [18,19,22,24].
PV701 (GroPep Limited, Thebarton, South Aus-
ralia, Australia) was manufactured by using cheese
hey obtained from Australian dairy cattle. The
ethod for enrichment of bioactive proteins in the
hey to produce PV701 has been described previously
27]. Brieﬂy, preclariﬁed whey was applied to a strong
ation-exchange resin, SP-Sepharose Big Beads (Am-
rsham-Pharmacia, Castle Hill, New South Wales,
ustralia), and the bound fraction containing bioactive
roteins was eluted in 0.5 mol/L NaCl at pH 6.5. The
luate was then concentrated and diaﬁltered into 150
mol/L NaCl. Activation of latent bioactive proteins
as achieved by transient acidiﬁcation of the eluate
efore passage through a 0.2-m ﬁnal ﬁlter to yield a
ow-bioburden concentrate. The concentrate was then
iluted with 150 mmol/L sterile saline to obtain the
nal formulation.
V701 Administration and Dosing
The primary end point of this open-label phase Ib
rial was to evaluate the safety and tolerability of
V701 administered as a mouthwash. Secondary end
oints included measurement of PV701 serum anti-
odies and evaluation of the preliminary efﬁcacy of
he trial drug. PV701 (15 mL) was administered 6
imes a day for 12 days, commencing on the day of the
rst dose of BEAM (day 6) and continuing to day
5. Before each PV701 treatment, patients rinsed
heir mouths with water and then administered and
etained the mouthwash in the oral cavity for at least
0 seconds before it was expelled.
Both the initial PV701 dose (13.5 mg/mL) and the
tudy design (one of dose de-escalation) were based on
oses deemed safe in the previous healthy volunteer
rial [24]. Six patients were planned to be accrued at
he highest dose. If patients were poorly compliant
ith PV701 (10 doses missed over the administra-
ion period), were admitted to the ICU, or died for
easons believed to be unrelated to the trial medica-
ion, additional patients could be accrued at that dose.
LTs were deﬁned as grade 4 mucositis, grade 3
ucositis persisting beyond day 28, or any other
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Mucositis Therapy with Milk-Protein Extract
Brade 3 or 4 toxicity considered to be related to the
rial drug. If DLTs were identiﬁed in 2 or more
atients, it was planned to de-escalate to the lower
ose levels by using an identical dosing regimen. If
ewer than 2 of 6 patients developed DLT, then that
ose would be declared the maximum tolerated dose.
nti-PV701 Antibodies
Determination of the titer of PV701 antibodies in
atient sera was performed by enzyme-linked immu-
osorbent assay on trial entry, on day 6, and at the
xit evaluation (day 33).
egulatory Approval
The protocols for the collection of the historical
ontrol data and the phase Ib trial were reviewed and
pproved by the Institutional Scientiﬁc and Ethics
ommittees at PMCC. The Australian regulatory re-
uirements were met, and written informed consent
as obtained before patients commenced the phase Ib
rial procedures.
tatistical Analyses
The duration of grade3 OMwas measured from
he date on which OM was ﬁrst recorded as grade 3 or
until the date when it resolved to grade 2. The
uration of grade2 OM was measured from the date
n which OM was ﬁrst recorded as grade 2, 3, or 4
ntil the date when it recovered to grade 1. Dura-
ions were estimated by using the Kaplan-Meier
ethod with censoring for patients who died, were
ost to follow-up, were admitted to the ICU, or were
ischarged home. The duration of enteral or paren-
eral feeding was measured from the date the patient
ommenced enteral or parenteral feeding until the
ate all such feeding ceased, with censoring at the date
f death for patients who died while receiving total
arenteral nutrition. The duration of treatment with
V opiates was measured from the date of commenc-
ng to the date of ceasing the relevant medication,
ith censoring for patients who died, were lost to
ollow-up, were admitted to the ICU, or were dis-
harged home. The duration of time spent in the ICU
as measured from the date of ﬁrst admission to the
CU after commencing HDT to the date of ﬁnal
ischarge from the ICU, with censoring at the date of
eath for patients who died in the ICU.
For all Kaplan-Meier analyses, patients who did
ot reach the relevant grade of OM or who did not
equire feeding, ICU admission, or the relevant med-
cation were included in the Kaplan-Meier curves with
urations of 0 days. The Brookmeyer-Crowley method
as used to estimate 95% conﬁdence intervals for
edian durations. Ninety-ﬁve percent conﬁdence in-
ervals for the percentages of patients with durations
onger than 28 days (7 days for ICU) were calculated g
B&MTith the logit transformation. These time points were
hosen for convenience of reporting, independently of
omparative outcomes, because they were near the
nd of the Kaplan-Meier curves and corresponded to
ntire weeks. They were not used for statistical com-
arisons of the 2 groups.
Statistical comparisons between the 89 historical
ontrols and the 9 trial patients were performed by
sing the Fisher exact test for dichotomous data, the
ochran-Armitage test for trend for worst grade of
M, and the Mantel-Cox log-rank test for comparing
urations. Because of the small number of trial pa-
ients, conventional log-rank tests were deemed unre-
iable (the expected number of events is often 5), so
values calculated for log-rank tests were exact be-
ause they were based on the exact distribution of the
um of independent hypergeometric random vari-
bles. All tests were 2 sided, and the level of signiﬁ-
ance was P  .05 for each comparison. Percentage
ata given in tables were rounded off to the nearest
hole number and, hence, may not always add up to
00%.
ESULTS
atient Characteristics
A total of 9 patients were accrued before recruit-
ent ceased in the phase Ib trial. All received PV701
3.5 mg/mL. Dose reduction was not required be-
ause no DLTs were observed in the trial patients.
emographic and other baseline characteristics for
he 9 trial patients and the 89 historical controls are
ummarized in Table 1. There was no statistical dif-
erence between the groups with respect to all param-
ters analyzed, including age, sex, tumor responsive-
ess, and extent of prior chemotherapy (all data not
hown, but data from some of the historical control
atients have been reported previously [28]).
Of the 9 trial patients, 2 were withdrawn because
f nausea and vomiting related to HDT. Four of the 7
emaining patients who continued the full duration of
herapy missed 10 PV701 doses. The median and
ean number of doses received by these 7 patients
ere 63 and 62, respectively (88% and 86% of
lanned; range, 53%-69% and 74%-96% of planned,
espectively). It was clear by this stage that the criteria
f excluding patients who had missed 10 of the
lanned 72 doses were too stringent, and, given that 7
atients had received 53 doses and were evaluable
or tolerance and toxicity of PV701, the trial was
topped, and data were analyzed.
oxicity and Adverse Events
Altogether, 280 adverse events were recorded for
he 9 trial patients, but only 2 (grade 1 nausea and
rade 1 vomiting, both in patient 7) were assessed as
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5robably related to PV701. Fatigue and coexisting
ausea related to BEAM were the predominant rea-
ons for patients not receiving the planned 72 doses.
o biochemical or hematologic parameters seemed
ffected by PV701.
nti-PV701 Antibodies
Serum collected from trial patients at screening
howed a low level of reactivity toward PV701. Sig-
iﬁcant titers against bovine milk proteins have pre-
iously been described in healthy individuals [29]. It is
mportant to note that analysis of the postdose patient
era detected no signiﬁcant increase in antibodies to
V701 (P  .05).
ucositis, Enteral/Parenteral Feeding,
nd Analgesics
Table 2 details the OM severity grades reached by
he 9 PV701-treated patients and the 89 historical
ontrols. Comparative data for the duration of OM
rade 3 and grade 2 and duration of enteral/par-
nteral feeding and IV opiate administration are illus-
rated in Table 2 and in Kaplan-Meier plots (Figures
-4). PV701-treated patients had signiﬁcantly less se-
ere OM (grade 2) than the historical controls (78%
able 1. Patient Demographics and Other Baseline Characteristics
Variable
otal
ex
Male
Female
edian years of age at autologous stem cell transplantation (ran
odgkin lymphoma
on-Hodgkin lymphoma
able 2. Mucositis Severity and Use of Enteral/Parenteral Feeding and
Variable P
orst grade of NCI-CTC (BMT) oral mucositis, % (n)
0
1
2
3
4
ays of grade 3 oral mucositis (95% CI)
ays of grade 2 oral mucositis (95% CI)†
With any enteral feeding, TPN, or both
ays of enteral feeding, TPN, or both (95% CI)
With any intravenous opiates
ays of intravenous opiates (95% CI)
I indicates conﬁdence interval; NCI-CTC (BMT), National Can
TPN, total parenteral nutrition.
Log-rank test.
Denotes mucositis experienced before/after grade 3 mucositis.
Fisher exact test.
16ersus 100%; P  .0006; Cochran-Armitage test for
rend). In addition, PV701-treated patients had grade
3 OM for an estimated 5 fewer days than historical
ontrols (P  .0003; log-rank test). Trial patients also
xperienced a further 2 fewer days of grade 2 (devel-
ping or resolving) mucositis. Moreover, the need for
nd duration of supplemental enteral/parenteral feed-
ng and IV opiates was less, and no trial patients had
rolonged mucositis beyond 28 days. There was no
igniﬁcant difference between PV701-treated patients
nd historical controls with respect to requiring ICU
r length of stay in ICU (data not shown).
The severity of mucositis in the trial patients, as
raded by the oral assessment guide [26], is detailed in
able 3. Because this tool was not used for the his-
orical control group, no comparison could be made.
ISCUSSION
Results of the phase Ib trial demonstrated that
V701 (15 mL  13.5 mg/mL) was generally well
olerated and had no substantial side effects when
dministered 6 times a day after meals for 12 days,
ommencing on the ﬁrst day of administration of
EAM. However, patients could receive on average
PV701-Treated
Patients Historical Controls
n % n %
9 89
6 67 59 66
3 33 30 33
49 (32-68) 43 (18-67)
1 11 22 25
8 89 67 75
enous Opiates
Treated Patients Historical Controls P Value
.0006
0% (0) 0% (0)
2% (2) 0% (0)
1% (1) 0% (0)
7% (6) 100% (89)
0% (0) 0% (0)
5 (0-7) 10 (8-11) .0003*
11 (0-15) 13 (12-15) .002*
6% (5) 91% (81) .012‡
3 (0-12) 12 (9-12) .010*
8% (7) 98% (87) .022‡
4 (0-7) 9 (8-10) .0006*
titute Common Toxicity Criteria (bone marrow transplantation);ge)Intrav
V701-
2
1
6
6
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Bnly 86% of the planned dosage, primarily because of
oncomitant nausea related to BEAM. No increase in
ntibodies to the milk-derived proteins was detected
fter PV701 treatment.
Although this was not the primary end point of
ur trial, we compared the results of the 9 PV701-
reated patients with those of 89 historical control
atients previously treated with the same BEAM che-
otherapy and AuSCT regimen. Whereas 100% of
Figure 1. Kaplan-Meier plot o
Figure 2. Kaplan-Meier plot ofB&MThe historical control patients experienced grade 3
ucositis, only 67% of the PV701-treated patients
eveloped grade 3 mucositis. Furthermore, PV701-
reated patients had fewer days of both grade 2 and 3
ucositis. Comparison of the 2 data sets also showed
hat treatment with PV701 reduced other comorbidi-
ies, including the requirement for and duration of IV
piates and the requirement for and duration of en-
eral/parenteral feeding.
on of grade 3 oral mucositis.
on of grade 2 oral mucositis.f duratidurati517
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5These data suggest that treatment with PV701 ad-
inistered as a mouthwash was beneﬁcial in reducing
he severity and duration of OM. However, it is impor-
ant to note the deﬁciencies of the comparative aspects of
his study. First, in using historical controls, we are
omparing contemporary data with data from patients
reated over 10 years. Although our protocols for the
Figure 3. Kaplan-Meier plot of d
Figure 4. Kaplan-Meier plot of durati18anagement of mucositis did not alter substantially over
his period, it is likely that the instigation of treatments
uch as IV opiates or enteral/parenteral nutrition did
ary according to individual circumstances and physician
hoice and did not follow the same strict criteria as in the
rospective trial. Second, assessment of OM is subject to
nterobserver variation. Although all trial patients were
of enteral or parenteral feeding.
travenous (IV) opiate administration.urationon of in
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Bssessed by the same team, the reporting of mucositis in
he historical group would likely have varied somewhat.
hird, the current method of grading mucositis with
CI-CTC (BMT) is not optimal in separating OM
rom mucositis in the more distal gastrointestinal tract.
or example, mucositis is graded as 3 if enteral or par-
nteral feeding is required. However, the institution of
uch feeding is subject to indications other than purely
M, eg, severe diarrhea and poor oral intake without
ery severe oral ulceration. Nonetheless, the need for IV
piates is considered a good reﬂection of the severity of
M. Indeed, the 98% incidence in the control group as
ompared with the 78% in the trial cohort along with
he 5-day reduction in time on IV opiates suggest that
he use of PV701 affects mouth pain.
One further potential criticism of our study is that
he historical control group seemed to have a very
igh incidence of grade 3 mucositis (91% required
nteral/parenteral nutrition). Indeed, this seems to be
he case, with other studies reporting grade 3 mucosi-
is in 0% to 58% with durations varying from 0 to 11
ays [1-9]. These differences may in part be a reﬂec-
ion of various modiﬁcations of the BEAM regimen
eported, but they most likely reﬂect different meth-
ds of scoring and reporting mucositis. To illustrate
able 3. Severity of Mucositis Using the Oral Assessment Guide [25] f
Variable
oice
Normal
Deeper or raspy
Difficulty talking or painful
wallowing
Normal
Some pain
Unable
ips
Smooth, pink, and moist
Dry or cracked
Ulcerated or bleeding
ongue
Pink and moist and papillae present
Coated or loss of papillae with shiny appearance with or witho
Blistered or cracked
aliva
Watery
Thick or “ropey”
Absent
ucous membranes
Pink and moist
Reddened or coated without ulceration
Ulceration with or without bleeding
ingiva
Pink, stippled, and firm
Edematous with or without redness
Spontaneous bleeding or bleeding with pressure
eeth or dentures
Clean and no debris
Plaque or debris in localized areas
Plaque or debris generalized along gum line or denture-bearinhe point, the same group of authors report the need s
B&MTor parenteral nutrition as 18% to 76% with durations
f 0 to 24 days and the need for IV opiate use of 65%
o 78% (duration, 0-16 days). Given that nutritional
upport should equate to a classiﬁcation as grade 3
ucositis according to NCI-CTC (BMT) criteria,
his clearly has not been adhered to in most reported
tudies. Taken together, it seems that one cannot
ompare the data we report with those of other pub-
ished studies. Nonetheless, our data, which used
ore comprehensive methods for assessment of mu-
ositis, such as the oral assessment guide [26] and
isual analogue scales, provide a basis for future stud-
es.
Preventing grade 3 mucositis, or even reducing its
ncidence, results in beneﬁcial outcomes for patients
y decreasing associated complications. This could
educe the length of hospital stay and the overall costs
ssociated with care. We conclude that PV701 is easily
dministered as a mouthwash, has minimal side ef-
ects, and is an encouraging potential treatment op-
ion for mucositis in patients undergoing HDT and
uSCT. Furthermore, the mixture of naturally occur-
ing growth factors in PV701 may be cost-effective
hen compared with single recombinant growth fac-
ors. Despite the limitations described, including a
nts Who Received 53 Doses of PV701 (n  7)
Worst Grade n %
1 0 0
2 6 86
3 1 14
1 2 29
2 2 29
3 9 43
1 0 0
2 7 100
3 0 0
1 0 0
ess 2 5 71
3 2 29
1 1 14
2 5 71
3 1 14
1 0 0
2 2 29
3 5 71
1 1 14
2 6 86
3 0 0
1 4 57
2 1 14
3 2 29or Patie
ut rednmall sample size and comparisons with historical con-
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5rols, the results are encouraging, and further investi-
ation of this agent is warranted.
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